2017
Bidirectional Text Messaging to Monitor Endocrine Therapy Adherence and Patient-Reported Outcomes in Breast Cancer
Mougalian SS, Epstein LN, Jhaveri AP, Han G, Abu-Khalaf M, Hofstatter EW, DiGiovanna MP, Silber ALM, Adelson K, Pusztai L, Gross CP. Bidirectional Text Messaging to Monitor Endocrine Therapy Adherence and Patient-Reported Outcomes in Breast Cancer. JCO Clinical Cancer Informatics 2017, 1: 1-10. PMID: 30657377, DOI: 10.1200/cci.17.00015.Peer-Reviewed Original ResearchConceptsAdverse effectsEndocrine therapyClinical trialsBreast cancerFrequency of AEsMedication-related adverse effectsTherapy-related adverse effectsBidirectional Text MessagingEndocrine therapy adherenceAdjuvant endocrine therapyMajority of patientsMedical record reviewSevere adverse effectsText message systemConsecutive patientsVaginal symptomsRecord reviewHot flashesTherapy adherenceClinic nursesHistorical controlsPatient acceptanceProvider teamGeneral populationPatients
2015
Uptake of exemestane chemoprevention in postmenopausal women at increased risk for breast cancer
Aktas B, Sorkin M, Pusztai L, Hofstatter EW. Uptake of exemestane chemoprevention in postmenopausal women at increased risk for breast cancer. European Journal Of Cancer Prevention 2015, 25: 3-8. PMID: 25642790, PMCID: PMC4885537, DOI: 10.1097/cej.0000000000000124.Peer-Reviewed Original ResearchConceptsCancer prevention clinicSelective estrogen receptor modulatorsPostmenopausal womenEstrogen receptor modulatorsChemoprevention uptakePrevention clinicReceptor modulatorsBreast cancer chemopreventionRetrospective chart reviewSerious side effectsChemoprevention medicationsChemopreventive optionChart reviewMean ageAromatase inhibitorsBreast cancerBone densityStudy populationCancer chemopreventionGeneral populationExemestaneSide effectsChemopreventionClinicWomen
2013
Clinical experience with exemestane in postmenopausal women at increased risk of breast cancer.
Sorkin M, Lapolt D, Pusztai L, Hofstatter E. Clinical experience with exemestane in postmenopausal women at increased risk of breast cancer. Journal Of Clinical Oncology 2013, 31: 1565-1565. DOI: 10.1200/jco.2013.31.15_suppl.1565.Peer-Reviewed Original ResearchCancer prevention clinicPostmenopausal womenPrevention clinicBreast cancerRetrospective chart reviewPoor patient acceptancePatient acceptance rateRisk of thrombosisCancer chemoprevention agentsBreast atypiaChemoprevention medicationsChemoprevention uptakeChart reviewEligible womenPatient characteristicsPrevention settingMedication uptakeMean ageChemoprevention agentsMedical historyUterine cancerPatient acceptanceFamily historyGeneral populationExemestane